Follow Us on Google News
Africa to get state-of-art HIV drugs for $75 per patient a year
The drug was originally developed by ViiV Healthcare, the HIV business majority-owned by GlaxoSmithKline (GSK.L). ViiV has offered licensing deals to generic companies to sell low-cost versions of the medicine in poor countries.
Reuters
